Idorsia announced that the FDA after having released Tryvio (aprocitentan) from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on March 17, 2025), has now approved the… read more.
Johnson & Johnson MedTech announced 12-month results from the SmartfIRE study, presented as a late-breaking presentation at the annual meeting of the European Heart Rhythm Association (EHRA) in… read more.
Complications during pregnancy (or adverse pregnancy outcomes), like gestational diabetes and newly developed high blood pressure, act as nature’s stress test and may uncover an individual’s risk for heart… read more.
Heart attack/myocardial infarction (MI) patients treated early with cholesterol-lowering ezetimibe and a statin have achieved a significantly better prognosis than those who received ezetimibe later or not all…. read more.
A new analysis finds a significant uptick in the number of people dying at home due to ischemic stroke compared to inpatient medical facilities, and when not at… read more.
Novo Nordisk presented the full results from STRIDE, a phase III peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic (semaglutide 1.0 mg) in… read more.
Sudden cardiac death (SCD) refers to an unexpected death of a person, believed to be caused by a heart-related issue. It occurs within one hour of the onset… read more.
AbbVie announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual Meeting, April 25-30,… read more.
Mammograms, with the help of artificial intelligence (AI) models, may reveal much more than cancer, according to a study being presented at the American College of Cardiology’s Annual… read more.
Compared with people with elevated levels of low-density lipoprotein cholesterol (LDL-C), researchers report that people with lower levels of LDL-C have a relatively lower risk of developing dementia…. read more.
Abbott announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has… read more.
Researchers report a significantly increased risk of dementia in patients diagnosed with atrial fibrillation (AF) in midlife, and a significantly increased risk of early-onset dementia (EOD) as well…. read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
